Puma Biotechnology, Inc. PBYI · NASDAQ
$8.25 -15.56% (-$1.52)
Summary
78 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 211% a year over the last 3 years.
- It earns 18 USD a year on every 100 USD of invested capital.
- It has no debt and holds $41.5M in cash.
- Out of every 100 USD of revenue, 12 USD is left as net profit.
What to watch
- The share price is above the Bulios Fair Price.
- Revenue grew by only 0.0% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 18.9 USD for 1 USD of yearly profit. Over the last five years it was 23,762.8 USD on average.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 0.3% a year over 5 years. Over the last 3 years it grew by 0.0% a year. Earnings per share grew by 211% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 26 USD
- Research and development 32 USD
- Sales and administration 30 USD
- Taxes and other 1.0 USD
- Net profit 10 USD
Net profit, industry median (Biotechnology) -9.2 USD
Out of every 100 USD of revenue, 10 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt has no debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 8
- Hold 8
- Sell 4
No analyst has published a price target.
40% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 89%
- Royalty 11%
By region
The company reports no revenue by region.
Product brings in 89% of revenue. Royalty grew fastest, by 18% a year.
Segments in detail